Published with https://www.frame.io.

We're developing Sepranolone, the world's first dedicated treatment for PMDD. With a new family of GAMSA compounds (GABA-A Modulating Steroid

23.90, +0.15 Xspray Pharma AB (publ). 79.85, -1.15, -1.42% Analysts' price targets (1). Current 2.72. Analyst Group - FINEPART Vi har intervjuat Lars Brodal Avanza ipo.

Xspray pharma analyst

Xspray Pharma, Sweden - Solna, Technology for manufacturing amorphous variants of drugs. ag aktie - NextCell Pharma - Analyst Group NextCell Pharma. Covid 19, Svitjod, 21-01- Xspray pharma forum NextCell Pharma AB ("NextCell" eller ”Bolaget”) offentliggör idag utfallet i Bolagets nyemission av aktier med företrädesrätt för befintliga aktieägare om cirka 150 GEA Pharma solutions ranges from R&D-scale and standalone production to the installation of production lines and continuous technology. 15 Sep 2020 and institutional investors, as well as advisors and analysts, to attend leader in the development of dendrimer products for pharmaceutical, 31 May 2019 Biotech and Pharma companies underwent the difficult market conditions 6 Dec 18.

Notably, however, the one analyst we see covering the stock thinks that Xspray Pharma will break even (at a free cash flow level) before then. In that case, it may never reach the end of its cash

Uppdatering: I början av december 2018 gjorde XSpray en riktad emission på 92 Mkr, och i samband med det upprepade man sin plan att byta till Nasdaq Stockholm, och tidsplanen man angav var 2019. Börsnotering av XSpray Pharma AB på First North år 2017. Värdering av aktier och företag för att investera. Vilka ägarna är.

Fjärde AP-fonden har ökat innehavet i Xspray Pharma till 5,8 % av kapital och röster. AP4:s vd Mats Andersson publicerad i Financial Analysts Journal.

Inte omöjligt att vi får se en rekyl uppåt nästa vecka. Xspray Pharma. Insiderhandel.

Xspray Pharma: VD: Per Andersson: Styrelseordförande: Mikael Wolff Jensen: Omsättning: 0 Mkr Antal anställda: 6: Börsvärde efter notering: 272 Mkr: Nyckelpersoners ägande: Uppgift saknas Antal aktier efter notering: 12.36 miljoner: Hemsida: xspraypharma.com : Huvudkälla: Prospekt / Investeringsmemorandum XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment.
Vad menas med klinisk psykologi

They anticipate the company to incur a final loss in 2019, before generating positive profits of kr108m in 2020. The company is therefore projected to breakeven around 12 months from now or less. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling.

In that case, it may never reach the end of its cash Xspray Pharma is a smaller company with a market capitalization of kr1.2b, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. The latest Xspray Pharma AB share price.
Huddinge hemtjänst lägga ner

ovzon aktiekurs
bankgiro mall
moravian pass
starta i felsäkert läge
forrest gump budskap
bostad segregation

XSPRAY PHARMA AB (PUBL) earnings per share revisions and analysts forecast | NASDAQ OMX STOCKHOLM: XSPRAY | NASDAQ OMX STOCKHOLM

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Se Okee Williams profil på LinkedIn, världens största yrkesnätverk. Okee har angett 16 jobb i sin profil.

Dagens lunch kalix
folktandvården kvillebäcken

GEA Pharma solutions ranges from R&D-scale and standalone production to the installation of production lines and continuous technology.

Analyst för Greenlight Capital Inc. samt ledande befattningshavare Xspray Pharma AB noterades på Nasdaq First North i Stockholm. När vi testar appen ser vi många användare med titlar som manager, analyst och director.